Physiologic Expression of Sf3b1K700E Causes Impaired Erythropoiesis, Aberrant Splicing, and Sensitivity to Therapeutic Spliceosome Modulation

Cancer Cell

Volumn 30, Issue 3, 2016, Pages 404-417

  Obeng, Esther A ^a,b,c   Chappell, Ryan J ^c   Seiler, Michael ^d   Chen, Michelle C ^c   Campagna, Dean R ^b   Schmidt, Paul J ^b   Schneider, Rebekka K ^c   Lord, Allegra M ^c   Wang, Lili ^c   Gambe, Rutendo G ^c   McConkey, Marie E ^c   Ali, Abdullah M ^e   Raza, Azra ^e   Yu, Lihua ^d   Buonamici, Silvia ^d   Smith, Peter G ^d   Mullally, Ann ^c,f   Wu, Catherine J ^c,f   Fleming, Mark D ^b   Ebert, Benjamin L ^c,f  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b BOSTON CHILDREN S HOSPITAL   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d EISAI INC   (United States)

^e Department of Medicine   (United States)

^f BROAD INSTITUTE OF MIT AND HARVARD   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

E 7017; HEMATOLOGIC AGENT; SMALL NUCLEAR RIBONUCLEOPROTEIN; SPLICING FACTOR 3B SUBUNIT 1; UNCLASSIFIED DRUG; DNA BINDING PROTEIN; ONCOPROTEIN; PHOSPHOPROTEIN; RNA SPLICING FACTOR; SF3B1 PROTEIN, HUMAN; SF3B1 PROTEIN, MOUSE; TET2 PROTEIN, HUMAN; TET2 PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL EXPANSION; CELL MATURATION; CONTROLLED STUDY; ERYTHROID CELL; ERYTHROPOIESIS; GENE MUTATION; HEMATOPOIESIS; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; KNOCKOUT MOUSE; MACROCYTIC ANEMIA; MOUSE; MYELODYSPLASTIC SYNDROME; MYELOID PROGENITOR CELL; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RNA SPLICING; SPLICEOSOME; SPLICING DEFECT; ANIMAL; DEFICIENCY; GENETICS; METABOLISM; PHYSIOLOGY; POINT MUTATION; TRANSGENIC MOUSE;

ANIMALS; DNA-BINDING PROTEINS; ERYTHROPOIESIS; HEMATOPOIETIC STEM CELLS; HUMANS; MICE; MICE, TRANSGENIC; MYELODYSPLASTIC SYNDROMES; PHOSPHOPROTEINS; POINT MUTATION; PROTO-ONCOGENE PROTEINS; RNA SPLICING; RNA SPLICING FACTORS; SPLICEOSOMES;

EID: 84995618121     PISSN: 15356108     EISSN: 18783686     Source Type: Journal    
DOI: 10.1016/j.ccell.2016.08.006     Document Type: Article

References (55)

1. Allikmets, R., Raskind, W.H., Hutchinson, A., Schueck, N.D., Dean, M., Koeller, D.M., Mutation of a putative mitochondrial iron transporter gene (ABC7) in X-linked sideroblastic anemia and ataxia (XLSA/A). Hum. Mol. Genet. 8 (1999), 743–749.
2. Alsafadi, S., Houy, A., Battistella, A., Popova, T., Wassef, M., Henry, E., Tirode, F., Constantinou, A., Piperno-Neumann, S., Roman-Roman, S., et al. Cancer-associated SF3B1 mutations affect alternative splicing by promoting alternative branchpoint usage. Nat. Commun., 7, 2016, 10615.
3. Beachy, S.H., Aplan, P.D., Mouse models of myelodysplastic syndromes. Hematol. Oncol. Clin. North Am. 24 (2010), 361–375.
4. Becerra, S., Andres-Leon, E., Prieto-Sanchez, S., Hernandez-Munain, C., Sune, C., Prp40 and early events in splice site definition. Wiley Interdiscip. Rev. RNA 7 (2015), 17–32.
5. Bejar, R., Stevenson, K., Abdel-Wahab, O., Galili, N., Nilsson, B., Garcia-Manero, G., Kantarjian, H., Raza, A., Levine, R.L., Neuberg, D., Ebert, B.L., Clinical effect of point mutations in myelodysplastic syndromes. N. Engl. J. Med. 364 (2011), 2496–2506.
6. Bejar, R., Stevenson, K.E., Caughey, B.A., Abdel-Wahab, O., Steensma, D.P., Galili, N., Raza, A., Kantarjian, H., Levine, R.L., Neuberg, D., et al. Validation of a prognostic model and the impact of mutations in patients with lower-risk myelodysplastic syndromes. J. Clin. Oncol. 30 (2012), 3376–3382.
7. Boultwood, J., Pellagatti, A., Nikpour, M., Pushkaran, B., Fidler, C., Cattan, H., Littlewood, T.J., Malcovati, L., Della Porta, M.G., et al. The role of the iron transporter ABCB7 in refractory anemia with ring sideroblasts. PLoS One, 3, 2008, e1970.
8. Cartwright, G.E., Deiss, A., Sideroblasts, siderocytes, and sideroblastic anemia. N. Engl. J. Med. 292 (1975), 185–193.
9. Chen, M., Manley, J.L., Mechanisms of alternative splicing regulation: insights from molecular and genomics approaches. Nat. Rev. Mol. Cell Biol. 10 (2009), 741–754.
10. Darman, R.B., Seiler, M., Agrawal, A.A., Lim, K.H., Peng, S., Aird, D., Bailey, S.L., Bhavsar, E.B., Chan, B., Colla, S., et al. Cancer-associated SF3B1 hotspot mutations induce cryptic 3? splice site selection through use of a different branch point. Cell Rep. 13 (2015), 1033–1045.
11. DeBoever, C., Ghia, E.M., Shepard, P.J., Rassenti, L., Barrett, C.L., Jepsen, K., Jamieson, C.H., Carson, D., Kipps, T.J., Frazer, K.A., Transcriptome sequencing reveals potential mechanism of cryptic 3′ splice site selection in SF3B1-mutated cancers. PLoS Comput. Biol., 11, 2015, e1004105.
12. Eskens, F.A., Ramos, F.J., Burger, H., O'Brien, J.P., Piera, A., de Jonge, M.J., Mizui, Y., Wiemer, E.A., Carreras, M.J., Baselga, J., Tabernero, J., Phase I pharmacokinetic and pharmacodynamic study of the first-in-class spliceosome inhibitor E7107 in patients with advanced solid tumors. Clin. Cancer Res. 19 (2013), 6296–6304.
13. Folco, E.G., Coil, K.E., Reed, R., The anti-tumor drug E7107 reveals an essential role for SF3b in remodeling U2 snRNP to expose the branch point-binding region. Genes Dev. 25 (2011), 440–444.
14. Friedman, J.S., Lopez, M.F., Fleming, M.D., Rivera, A., Martin, F.M., Welsh, M.L., Boyd, A., Doctrow, S.R., Burakoff, S.J., SOD2-deficiency anemia: protein oxidation and altered protein expression reveal targets of damage, stress response, and antioxidant responsiveness. Blood 104 (2004), 2565–2573.
15. Garcia-Manero, G., Myelodysplastic syndromes: 2012 update on diagnosis, risk-stratification, and management. Am. J. Hematol. 87 (2012), 692–701.
16. Gozani, O., Feld, R., Reed, R., Evidence that sequence-independent binding of highly conserved U2 snRNP proteins upstream of the branch site is required for assembly of spliceosomal complex A. Genes Dev. 10 (1996), 233–243.
17. Gozani, O., Potashkin, J., Reed, R., A potential role for U2AF-SAP 155 interactions in recruiting U2 snRNP to the branch site. Mol. Cell Biol. 18 (1998), 4752–4760.
18. Haferlach, T., Nagata, Y., Grossmann, V., Okuno, Y., Bacher, U., Nagae, G., Schnittger, S., Sanada, M., Kon, A., Alpermann, T., et al. Landscape of genetic lesions in 944 patients with myelodysplastic syndromes. Leukemia 28 (2014), 241–247.
19. Hong, D.S., Kurzrock, R., Naing, A., Wheler, J.J., Falchook, G.S., Schiffman, J.S., Faulkner, N., Pilat, M.J., O'Brien, J., LoRusso, P., A phase I, open-label, single-arm, dose-escalation study of E7107, a precursor messenger ribonucleic acid (pre-mRNA) splicesome inhibitor administered intravenously on days 1 and 8 every 21 days to patients with solid tumors. Invest. New Drugs 32 (2014), 436–444.
20. Ishikawa, Y., Maeda, M., Pasham, M., Aguet, F., Tacheva-Grigorova, S.K., Masuda, T., Yi, H., Lee, S.U., Xu, J., Teruya-Feldstein, J., et al. Role of the clathrin adaptor PICALM in normal hematopoiesis and polycythemia vera pathophysiology. Haematologica 100 (2014), 439–451.
21. Jaisser, F., Inducible gene expression and gene modification in transgenic mice. J. Am. Soc. Nephrol. 11:Suppl 16 (2000), S95–S100.
22. Kaida, D., Motoyoshi, H., Tashiro, E., Nojima, T., Hagiwara, M., Ishigami, K., Watanabe, H., Kitahara, T., Yoshida, T., Nakajima, H., et al. Spliceostatin A targets SF3b and inhibits both splicing and nuclear retention of pre-mRNA. Nat. Chem. Biol. 3 (2007), 576–583.
23. Keyhani, M., Giuliani, D., Giuliani, E.R., Morse, B.S., Erythropoiesis in pyridoxine deficient mice. Proc. Soc. Exp. Biol. Med. 146 (1974), 114–119.
24. Kim, E., Ilagan, J.O., Liang, Y., Daubner, G.M., Lee, S.C., Ramakrishnan, A., Li, Y., Chung, Y.R., Micol, J.B., Murphy, M.E., et al. SRSF2 mutations contribute to myelodysplasia by mutant-specific effects on exon recognition. Cancer Cell 27 (2015), 617–630.
25. Kotake, Y., Sagane, K., Owa, T., Mimori-Kiyosue, Y., Shimizu, H., Uesugi, M., Ishihama, Y., Iwata, M., Mizui, Y., Splicing factor SF3b as a target of the antitumor natural product pladienolide. Nat. Chem. Biol. 3 (2007), 570–575.
26. Kramer, A., The structure and function of proteins involved in mammalian pre-mRNA splicing. Annu. Rev. Biochem. 65 (1996), 367–409.
27. Kuhn, R., Schwenk, F., Aguet, M., Rajewsky, K., Inducible gene targeting in mice. Science 269 (1995), 1427–1429.
28. Langemeijer, S.M., Kuiper, R.P., Berends, M., Knops, R., Aslanyan, M.G., Massop, M., Stevens-Linders, E., van Hoogen, P., van Kessel, A.G., Raymakers, R.A., et al. Acquired mutations in TET2 are common in myelodysplastic syndromes. Nat. Genet. 41 (2009), 838–842.
29. Liu, J., Zhang, J., Ginzburg, Y., Li, H., Xue, F., De Franceschi, L., Chasis, J.A., Mohandas, N., An, X., Quantitative analysis of murine terminal erythroid differentiation in vivo: novel method to study normal and disordered erythropoiesis. Blood 121 (2013), e43–e49.
30. Malcovati, L., Papaemmanuil, E., Bowen, D.T., Boultwood, J., Della Porta, M.G., Pascutto, C., Travaglino, E., Groves, M.J., Godfrey, A.L., Ambaglio, I., et al. Clinical significance of SF3B1 mutations in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms. Blood 118 (2011), 6239–6246.
31. Matsunawa, M., Yamamoto, R., Sanada, M., Sato-Otsubo, A., Shiozawa, Y., Yoshida, K., Otsu, M., Shiraishi, Y., Miyano, S., Isono, K., et al. Haploinsufficiency of Sf3b1 leads to compromised stem cell function but not to myelodysplasia. Leukemia 28 (2014), 1844–1850.
32. Mizui, Y., Sakai, T., Iwata, M., Uenaka, T., Okamoto, K., Shimizu, H., Yamori, T., Yoshimatsu, K., Asada, M., Pladienolides, new substances from culture of Streptomyces platensis Mer-11107. III. In vitro and in vivo antitumor activities. J. Antibiot. 57 (2004), 188–196.
33. Moran-Crusio, K., Reavie, L., Shih, A., Abdel-Wahab, O., Ndiaye-Lobry, D., Lobry, C., Figueroa, M.E., Vasanthakumar, A., Patel, J., Zhao, X., et al. Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation. Cancer Cell 20 (2011), 11–24.
34. Mufti, G.J., Bennett, J.M., Goasguen, J., Bain, B.J., Baumann, I., Brunning, R., Cazzola, M., Fenaux, P., Germing, U., Hellstrom-Lindberg, E., et al. Diagnosis and classification of myelodysplastic syndrome: International Working Group on Morphology of myelodysplastic syndrome (IWGM-MDS) consensus proposals for the definition and enumeration of myeloblasts and ring sideroblasts. Haematologica 93 (2008), 1712–1717.
35. Nakajima, H., Hori, Y., Terano, H., Okuhara, M., Manda, T., Matsumoto, S., Shimomura, K., New antitumor substances, FR901463, FR901464 and FR901465. II. Activities against experimental tumors in mice and mechanism of action. J. Antibiot. 49 (1996), 1204–1211.
36. Nakajima, H., Sato, B., Fujita, T., Takase, S., Terano, H., Okuhara, M., New antitumor substances, FR901463, FR901464 and FR901465. I. Taxonomy, fermentation, isolation, physico-chemical properties and biological activities. J. Antibiot. 49 (1996), 1196–1203.
37. Papaemmanuil, E., Cazzola, M., Boultwood, J., Malcovati, L., Vyas, P., Bowen, D., Pellagatti, A., Wainscoat, J.S., Hellstrom-Lindberg, E., Gambacorti-Passerini, C., et al. Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts. N. Engl. J. Med. 365 (2011), 1384–1395.
38. Pellagatti, A., Cazzola, M., Giagounidis, A.A., Malcovati, L., Porta, M.G., Killick, S., Campbell, L.J., Wang, L., Langford, C.F., Fidler, C., et al. Gene expression profiles of CD34+ cells in myelodysplastic syndromes: involvement of interferon-stimulated genes and correlation to FAB subtype and karyotype. Blood 108 (2006), 337–345.
39. Pondarre, C., Campagna, D.R., Antiochos, B., Sikorski, L., Mulhern, H., Fleming, M.D., Abcb7, the gene responsible for X-linked sideroblastic anemia with ataxia, is essential for hematopoiesis. Blood 109 (2007), 3567–3569.
40. Quivoron, C., Couronne, L., Della Valle, V., Lopez, C.K., Plo, I., Wagner-Ballon, O., Do Cruzeiro, M., Delhommeau, F., Arnulf, B., Stern, M.H., et al. TET2 inactivation results in pleiotropic hematopoietic abnormalities in mouse and is a recurrent event during human lymphomagenesis. Cancer Cell 20 (2011), 25–38.
41. Ren, S., Peng, Z., Mao, J.H., Yu, Y., Yin, C., Gao, X., Cui, Z., Zhang, J., Yi, K., Xu, W., et al. RNA-seq analysis of prostate cancer in the Chinese population identifies recurrent gene fusions, cancer-associated long noncoding RNAs and aberrant alternative splicings. Cell Res. 22 (2012), 806–821.
42. Roy, S.W., Gilbert, W., The evolution of spliceosomal introns: patterns, puzzles and progress. Nat. Rev. Genet. 7 (2006), 211–221.
43. Shirai, C.L., Ley, J.N., White, B.S., Kim, S., Tibbitts, J., Shao, J., Ndonwi, M., Wadugu, B., Duncavage, E.J., Okeyo-Owuor, T., et al. Mutant U2AF1 expression alters hematopoiesis and Pre-mRNA splicing in vivo. Cancer Cell 27 (2015), 631–643.
44. Socolovsky, M., Nam, H., Fleming, M.D., Haase, V.H., Brugnara, C., Lodish, H.F., Ineffective erythropoiesis in Stat5a(-/-)5b(-/-) mice due to decreased survival of early erythroblasts. Blood 98 (2001), 3261–3273.
45. Vardiman, J.W., Harris, N.L., Brunning, R.D., The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 100 (2002), 2292–2302.
46. Visconte, V., Makishima, H., Jankowska, A., Szpurka, H., Traina, F., Jerez, A., O'Keefe, C., Rogers, H.J., Sekeres, M.A., Maciejewski, J.P., Tiu, R.V., SF3B1, a splicing factor is frequently mutated in refractory anemia with ring sideroblasts. Leukemia 26 (2012), 542–545.
47. Visconte, V., Rogers, H.J., Singh, J., Barnard, J., Bupathi, M., Traina, F., McMahon, J., Makishima, H., Szpurka, H., Jankowska, A., et al. SF3B1 haploinsufficiency leads to formation of ring sideroblasts in myelodysplastic syndromes. Blood 120 (2012), 3173–3186.
48. Visconte, V., Tabarroki, A., Zhang, L., Parker, Y., Hasrouni, E., Mahfouz, R., Isono, K., Koseki, H., Sekeres, M.A., Saunthararajah, Y., et al. Splicing factor 3b subunit 1 (Sf3b1) haploinsufficient mice display features of low risk Myelodysplastic syndromes with ring sideroblasts. J. Hematol. Oncol., 7, 2014, 89.
49. Wang, L., Lawrence, M.S., Wan, Y., Stojanov, P., Sougnez, C., Stevenson, K., Werner, L., Sivachenko, A., DeLuca, D.S., Zhang, L., et al. SF3B1 and other novel cancer genes in chronic lymphocytic leukemia. N. Engl. J. Med. 365 (2011), 2497–2506.
50. Wang, C., Sashida, G., Saraya, A., Ishiga, R., Koide, S., Oshima, M., Isono, K., Koseki, H., Iwama, A., Depletion of Sf3b1 impairs proliferative capacity of hematopoietic stem cells but is not sufficient to induce myelodysplasia. Blood 123 (2014), 3336–3343.
51. Welch, J.S., Ley, T.J., Link, D.C., Miller, C.A., Larson, D.E., Koboldt, D.C., Wartman, L.D., Lamprecht, T.L., Liu, F., Xia, J., et al. The origin and evolution of mutations in acute myeloid leukemia. Cell 150 (2012), 264–278.
52. Will, C.L., Luhrmann, R., Spliceosome structure and function. Cold Spring Harb. Perspect. Biol., 3, 2011, 10.1101/cshperspect.a003707.
53. Yoshida, K., Sanada, M., Shiraishi, Y., Nowak, D., Nagata, Y., Yamamoto, R., Sato, Y., Sato-Otsubo, A., Kon, A., Nagasaki, M., et al. Frequent pathway mutations of splicing machinery in myelodysplasia. Nature 478 (2011), 64–69.
54. Zhang, J., Socolovsky, M., Gross, A.W., Lodish, H.F., Role of Ras signaling in erythroid differentiation of mouse fetal liver cells: functional analysis by a flow cytometry-based novel culture system. Blood 102 (2003), 3938–3946.
55. Zhou, Q., Derti, A., Ruddy, D., Rakiec, D., Kao, I., Lira, M., Gibaja, V., Chan, H., Yang, Y., Min, J., et al. A chemical genetics approach for the functional assessment of novel cancer genes. Cancer Res. 75 (2015), 1949–1958.